Medpace Holdings Inc 2026年季度报告

FORM 10-Q___________________________________________ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March31, 2026 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromto.Commission file number: 001-37856___________________________________________ Medpace Holdings, Inc.(Exact name of registrant as specified in its charter) ___________________________________________ 5375 Medpace Way, Cincinnati, OH 45227(Address of principal executive offices) (Zip Code) (513) 579-9911(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filerEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNoIndicate the number of shares outstanding of each of the issuer’s classes of Common Stock, as of the latest practicable date. MEDPACE HOLDINGS, INC. AND SUBSIDIARIESFORM 10-QFOR QUARTERLY PERIOD ENDED MARCH 31, 2026 TABLE OF CONTENTS Item Number PagePART I — FINANCIAL INFORMATION3Item 1.Financial Statements (unaudited)3Condensed Consolidated Balance Sheets as of March 31, 2026and December 31, 20253Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 20254Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2026and 20255Condensed Consolidated Statements of Shareholders’ Equity for the three months ended March 31, 2026 and20256Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 20257Notes to Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures About Market Risk24Item 4.Controls and Procedures24 PART II — OTHER INFORMATION Item 1.Legal Proceedings25Item 1A.Risk Factors25Item 2.Unregistered Sales of Equity Securities and Use of Proceeds25Item 3.Defaults Upon Senior Securities25Item 4.Mine Safety Disclosures25Item 5.Other Information25Item 6.Exhibits25EXHIBIT INDEX26SIGNATURES27 MEDPACE HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Amounts in thousands, except share amounts) MEDPACE HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Amounts in thousands, except per share amounts) MEDPACE HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Amounts in thousands) MEDPACE HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Amounts in thousands) MEDPACE HOLDINGS, INC. AND SUBSIDIARIESNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)March31, 2026 (1) Basis of Presentation Description of Business Medpace Holdings, Inc. (together with its subsidiaries, “Medpace” or the “Company”), a Delaware corporation, is a global provider ofclinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology,and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus onfull service Phase I-IV clinical development services and include development plan design, project management, regulatory affairs,clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, post-marketing clinicalsupport, laboratory services, clinical human pharmacology, imaging services, and electrocardio